Minimally Invasive Surfactant Therapy Followed by CPAP (MISTCPAP) in Preterm Infants With RDS
Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
There is a reducing incidence of pneumothorax, PIE and the combined outcome of death or BPD
since the development of Surfactant therapy. A policy of intubation with surfactant
administration and mechanical ventilation has become a standard therapy of infants at high
risk of RDS. However, initial stabilization with CPAP and, if necessary, given rescue
surfactant therapy has remained the standard therapy for preterm infants. Evidence reveals
similar results with regard to mortality and neonatal morbidity between the above two
strategies. The investigators intend to develop a method of minimally invasive surfactant
therapy followed by early CPAP (MISTCPAP) in preterm Infants with high risk of RDS for
improving the outcomes and reducing the incidence of BPD.